Nivalis shares in meltdown as cystic fibrosis promise withers in PhII flop
Eighteen months ago, little Nivalis Therapeutics managed to catch the tail winds of a long-running biotech IPO market and ride it to a $77 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
